Marinus Pharmaceuticals, Inc. (0JYL.L)
| Previous close | 1.5050 |
| Open | 1.5600 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.5600 - 1.5600 |
| 52-week range | 1.5600 - 11.2400 |
| Volume | |
| Avg. volume | 499 |
| Market cap | 70.521M |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
RADNOR, Pa., May 17, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in the global Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults.
- Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
RADNOR, Pa., May 08, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2024.
- Business Wire
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
RADNOR, Pa., May 02, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference.
